MCID: HMN036
MIFTS: 58

Hemangiopericytoma, Malignant

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Hemangiopericytoma, Malignant

MalaCards integrated aliases for Hemangiopericytoma, Malignant:

Name: Hemangiopericytoma, Malignant 57 12 71
Hemangiopericytoma 12 74 20 54 44 15 71
Solitary Fibrous Tumor/hemangiopericytoma 58
Haemangiopericytic Meningioma 12
Malignant Hemangiopericytoma 12
Solitary Fibrous Tumor 71
Sft/hpc 58

Characteristics:

Orphanet epidemiological data:

58
solitary fibrous tumor/hemangiopericytoma
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal recessive


HPO:

31
hemangiopericytoma, malignant:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:264
OMIM® 57 234820
MeSH 44 D006393
NCIt 50 C3087
SNOMED-CT 67 134335004
MESH via Orphanet 45 D006393
ICD10 via Orphanet 33 D21.9
UMLS via Orphanet 72 C0018922 C1266119
Orphanet 58 ORPHA2126
MedGen 41 C0334542
UMLS 71 C0018922 C0334542 C1266119

Summaries for Hemangiopericytoma, Malignant

GARD : 20 Hemangiopericytoma is a term used to described a group of tumors that are derived from pericytes, the cells normally arranged along specific types of blood vessels called capillaries and venules. These types of tumors are typically slow-growing, may be either benign (non-cancerous) or malignant (cancerous), and may occur anywhere in the body.

MalaCards based summary : Hemangiopericytoma, Malignant, also known as hemangiopericytoma, is related to meninges hemangiopericytoma and retroperitoneal hemangiopericytoma. An important gene associated with Hemangiopericytoma, Malignant is NAB2 (NGFI-A Binding Protein 2), and among its related pathways/superpathways are Innate Immune System and Pathways in cancer. The drugs Axitinib and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and liver, and related phenotypes are fatigue and weight loss

Disease Ontology : 12 A soft tissue cancer that is a soft tissue sarcoma and originates in the pericytes in the walls of capillaries.

Wikipedia : 74 A hemangiopericytoma is a type of soft-tissue sarcoma that originates in the pericytes in the walls of... more...

More information from OMIM: 234820

Related Diseases for Hemangiopericytoma, Malignant

Diseases in the Hemangiopericytoma, Malignant family:

Adult Malignant Hemangiopericytoma

Diseases related to Hemangiopericytoma, Malignant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 541)
# Related Disease Score Top Affiliating Genes
1 meninges hemangiopericytoma 32.4 STAT6 NAB2 IGF2 CD34
2 retroperitoneal hemangiopericytoma 32.3 PECAM1 KIT CD34
3 kidney hemangiopericytoma 32.1 SSX2 SS18 IGF2 CD34
4 secretory meningioma 31.5 VIM SERPINA3 MUC1
5 rare tumor 31.4 KIT DES ACTC1
6 meningioma, familial 31.0 VIM SERPINA3 S100B MUC1 IGF2 CD34
7 hemangioma 30.6 PECAM1 KIT IGF2 CD34 ACTC1
8 liposarcoma 30.5 VIM STAT6 MDM2 DES CD34
9 mesenchymal chondrosarcoma 30.5 VIM MUC1 DES
10 pleomorphic lipoma 30.5 SERPINA3 MDM2 CD34
11 vascular cancer 30.4 SERPINA3 PECAM1 KIT CD34 CALD1
12 myopericytoma 30.4 S100B ACTC1
13 fibrosarcoma 30.4 VIM KIT DES ACTC1
14 infantile myofibromatosis 30.4 VIM DES CD34 CALD1 ACTC1
15 angiosarcoma 30.3 VIM PECAM1 MUC1 KIT CD34
16 nasal cavity benign neoplasm 30.3 STAT6 NAB2 KIT CD34
17 tumor of meninges 30.2 VIM F13A1
18 angiomyolipoma 30.2 VIM KIT DES ACTC1
19 myofibroma 30.1 SERPINA3 F13A1 DES CD34 CALD1
20 chondrosarcoma 30.1 VIM SERPINA3 S100B MUC1 MDM2
21 congenital fibrosarcoma 30.1 VIM SERPINA3 DES ACTC1
22 cystadenocarcinoma 30.1 VIM SERPINA3 MUC1 ACTC1
23 mucinous cystadenocarcinoma 30.1 VIM MUC1 ACTC1
24 fibrous meningioma 30.1 VIM S100B NAB2 MUC1 F13A1 CD34
25 spindle cell lipoma 30.0 VIM NAB2 MDM2 DES CD34 ACTC1
26 intravascular papillary endothelial hyperplasia 30.0 VIM SERPINA3 ACTC1
27 leiomyoma 30.0 VIM KIT IGF2 DES CD34 ACTC1
28 liver angiosarcoma 30.0 VIM PECAM1
29 hemangioblastoma 30.0 VIM S100B PECAM1 MUC1 CD34
30 mesenchymal cell neoplasm 30.0 SSX2 SERPINA3 PECAM1 NAB2 KIT FGF23
31 uterine corpus sarcoma 30.0 KIT CD34 CALD1
32 chordoid meningioma 30.0 VIM S100B MUC1
33 cellular leiomyoma 30.0 DES CALD1
34 malignant triton tumor 30.0 S100B DES
35 cellular ependymoma 29.9 VIM S100B MUC1
36 intussusception 29.9 PECAM1 KIT CD34
37 lymphangioma 29.9 VIM SERPINA3 PECAM1 CD34 ACTC1
38 cavernous hemangioma 29.9 VIM PECAM1 MUC1 KIT DES CD34
39 myoma 29.9 KIT CD34 CALD1 ACTC1
40 clear cell meningioma 29.8 VIM S100B MUC1 CD34
41 myxoid liposarcoma 29.8 SSX2 SSX1 SS18 MDM2
42 neurilemmoma 29.8 VIM SERPINA3 S100B NGFR MUC1 KIT
43 cellular schwannoma 29.8 SSX1 SS18 CD34
44 connective tissue benign neoplasm 29.8 SERPINA3 PECAM1 MDM2 KIT CD34 CALD1
45 malignant spindle cell melanoma 29.7 SERPINA3 NGFR KIT CD34
46 neuroma 29.7 SERPINA3 S100B MUC1 CD34
47 lung sarcoma 29.7 SSX2 SSX1 SERPINA3 CD34
48 carcinosarcoma 29.7 VIM MUC1 KIT DES ACTC1
49 malignant mesenchymoma 29.7 SSX2 SERPINA3 MDM2 DES CD34 CALD1
50 lipomatosis, multiple 29.7 SERPINA3 PECAM1 MDM2 KIT DES CD34

Graphical network of the top 20 diseases related to Hemangiopericytoma, Malignant:



Diseases related to Hemangiopericytoma, Malignant

Symptoms & Phenotypes for Hemangiopericytoma, Malignant

Human phenotypes related to Hemangiopericytoma, Malignant:

58 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
2 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
3 neoplasia of the pleura 58 31 occasional (7.5%) Occasional (29-5%) HP:0100527
4 soft tissue neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0031459
5 diplopia 58 31 very rare (1%) Very rare (<4-1%) HP:0000651
6 constipation 58 31 very rare (1%) Very rare (<4-1%) HP:0002019
7 fever 58 31 very rare (1%) Very rare (<4-1%) HP:0001945
8 neoplasm of the lung 58 31 very rare (1%) Very rare (<4-1%) HP:0100526
9 abnormality of the peritoneum 58 31 very rare (1%) Very rare (<4-1%) HP:0002585
10 neoplasm of the nervous system 58 31 very rare (1%) Very rare (<4-1%) HP:0004375
11 neoplasm of the liver 58 31 very rare (1%) Very rare (<4-1%) HP:0002896
12 recurrent hypoglycemia 58 31 very rare (1%) Very rare (<4-1%) HP:0001988
13 urinary retention 58 31 very rare (1%) Very rare (<4-1%) HP:0000016
14 loss of consciousness 58 31 very rare (1%) Very rare (<4-1%) HP:0007185
15 vaginal neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0100650
16 uterine neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0010784
17 abnormality of the mediastinum 58 31 very rare (1%) Very rare (<4-1%) HP:0045026
18 night sweats 58 31 very rare (1%) Very rare (<4-1%) HP:0030166
19 abnormality of the forehead 58 31 very rare (1%) Very rare (<4-1%) HP:0000290
20 hypophosphatemic rickets 58 31 very rare (1%) Very rare (<4-1%) HP:0004912
21 hypoinsulinemia 58 31 very rare (1%) Very rare (<4-1%) HP:0040216
22 prostate cancer 58 31 very rare (1%) Very rare (<4-1%) HP:0012125
23 pelvic mass 58 31 very rare (1%) Very rare (<4-1%) HP:0031501
24 low back pain 58 31 very rare (1%) Very rare (<4-1%) HP:0003419
25 reduced c-peptide level 58 31 very rare (1%) Very rare (<4-1%) HP:0030795
26 abnormality of the cardiovascular system 31 HP:0001626
27 hypoglycemia 58 Very rare (<4-1%)
28 neoplasm 58 Occasional (29-5%)
29 abnormality of the prostate 58 Very rare (<4-1%)
30 genital neoplasm 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Vascular:
malignant hemangiopericytoma

Clinical features from OMIM®:

234820 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Hemangiopericytoma, Malignant:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 ACTC1 CD34 DES F13A1 FGF23 IGF2
2 cardiovascular system MP:0005385 10.14 ACTC1 DES F13A1 FGF23 IGF2 KIT
3 cellular MP:0005384 10.11 ACTC1 CD34 DES IGF2 KIT MDM2
4 hematopoietic system MP:0005397 10.1 ACTC1 CD34 F13A1 FGF23 IGF2 KIT
5 integument MP:0010771 9.9 CD34 F13A1 FGF23 IGF2 KIT MDM2
6 muscle MP:0005369 9.56 ACTC1 DES IGF2 KIT MDM2 NGFR
7 respiratory system MP:0005388 9.28 F13A1 FGF23 IGF2 KIT NAB2 NGFR

Drugs & Therapeutics for Hemangiopericytoma, Malignant

Drugs for Hemangiopericytoma, Malignant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
2
Bevacizumab Approved, Investigational Phase 2 216974-75-3
3
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
4
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
5
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
6
Gemcitabine Approved Phase 2 95058-81-4 60750
7
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166 2942
8
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
9
Pembrolizumab Approved Phase 2 1374853-91-4
10
Ifosfamide Approved Phase 2 3778-73-2 3690
11
Imidacloprid Vet_approved Phase 1, Phase 2 105827-78-9 86418
12 Protein Kinase Inhibitors Phase 2
13 Imatinib Mesylate Phase 2 220127-57-1 123596
14 Antibiotics, Antitubercular Phase 2
15 Anti-Bacterial Agents Phase 2
16 Angiogenesis Inhibitors Phase 2
17 Immunologic Factors Phase 2
18 Immunoglobulins Phase 2
19 Antibodies Phase 2
20 Immunoglobulins, Intravenous Phase 2
21 Antibodies, Monoclonal Phase 2
22 Anti-Infective Agents Phase 2
23 Antiviral Agents Phase 2
24 Cytochrome P-450 Enzyme Inhibitors Phase 2
25 Cytochrome P-450 CYP3A Inhibitors Phase 2
26 Immunosuppressive Agents Phase 2
27 Antimetabolites Phase 2
28 Antineoplastic Agents, Immunological Phase 2
29 Alkylating Agents Phase 2
30
Isophosphamide mustard Phase 2 100427
31
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
32
Aldesleukin Approved Phase 1 110942-02-4, 85898-30-2
33
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
34
Etanidazole Investigational Phase 1 22668-01-5
35
Liposomal doxorubicin Phase 1 31703
36 Analgesics, Non-Narcotic Phase 1
37 Anti-HIV Agents Phase 1
38 glucocorticoids Phase 1
39 Interleukin-2 Phase 1
40 Analgesics Phase 1
41 Anti-Retroviral Agents Phase 1
42 Fluorides Phase 1
43
Pentetic acid Approved 67-43-6
44
Edetic Acid Approved, Vet_approved 60-00-4, 62-33-9 6049
45
Iron Approved 7439-89-6 23925 29936
46 Protective Agents
47 Iron Chelating Agents
48 Chelating Agents
49 Antidotes

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor Unknown status NCT02261207 Phase 2 Axitinib
3 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
4 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
5 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
6 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
9 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
10 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
11 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
12 A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations Recruiting NCT04094610 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
13 Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients Recruiting NCT03023124 Phase 2 Trabectedin;Adriamycin;Dacarbazine
14 ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING) Recruiting NCT03840772 Phase 2 Eribulin
15 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
16 A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) Active, not recruiting NCT02066285 Phase 2 Pazopanib
17 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Active, not recruiting NCT01117844 Phase 1, Phase 2
18 S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors Terminated NCT00003292 Phase 2 ifosfamide
19 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
20 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
21 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
22 Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors Terminated NCT00110032 Phase 1 EF5
23 Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. A Multicenter Study. Unknown status NCT01694654
24 Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma Recruiting NCT02613312
25 Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma Recruiting NCT02613299
26 Staging Procedures to Diagnose Malignant Pleural Mesothelioma Recruiting NCT02648763
27 Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology Recruiting NCT04648462
28 Yoga and Brain Cancer: A Feasibility Study Terminated NCT01234805
29 Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions Terminated NCT02967380 Gadobenate Dimeglumine;Gadobutrol
30 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452

Search NIH Clinical Center for Hemangiopericytoma, Malignant

Cochrane evidence based reviews: hemangiopericytoma

Genetic Tests for Hemangiopericytoma, Malignant

Anatomical Context for Hemangiopericytoma, Malignant

MalaCards organs/tissues related to Hemangiopericytoma, Malignant:

40
Lung, Bone, Liver, Brain, Kidney, Breast, Prostate

Publications for Hemangiopericytoma, Malignant

Articles related to Hemangiopericytoma, Malignant:

(show top 50) (show all 2512)
# Title Authors PMID Year
1
Malignant hemangiopericytoma in three kindred members of one family. 61 57
3338042 1988
2
Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma. 54 61
19383775 2009
3
Fibrous histiocytoma of the lacrimal gland. 61 54
17413632 2007
4
[Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma]. 61 54
12571793 2003
5
Iatrogenic implantation of malignant meningioma to the abdominal wall. 61 54
11315631 2001
6
The expression and role of insulin-like growth factor II in malignant hemangiopericytomas. 61 54
10682323 1999
7
Factor XIIIa-immunoreactivity in tumors of the central nervous system. 61 54
9561329 1998
8
Uterine angiosarcomas: a morphologic and immunohistochemical study of four cases. 61 54
9500227 1998
9
Insulin-like growth factor II expression in primary meningeal hemangiopericytoma and its metastasis to the liver accompanied by hypoglycemia. 61 54
8760024 1996
10
Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma. 61 54
8772551 1996
11
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. 61 54
8064888 1994
12
[A comparative study of "angioblastic meningioma", hemangiopericytoma and cerebellar hemangioblastoma]. 61 54
8340101 1993
13
The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. 61 54
1712541 1991
14
The immunophenotype of hemangiopericytomas and glomus tumors, with special reference to muscle protein expression: an immunohistochemical study and review of the literature. 61 54
1708501 1991
15
Intermediate filament proteins and actin isoforms as markers for soft-tissue tumor differentiation and origin. III. Hemangiopericytomas and glomus tumors. 61 54
2158236 1990
16
Coexistence of Conventional Leiomyoma, Fumarate Hydratase-deficient Atypical Leiomyoma, and Perivascular Epithelioid Cell Tumor in a Uterus: A Case Study. 61
32265359 2021
17
Primary cutaneous synovial sarcoma-Sometimes the hoof beats are zebras. 61
32515062 2021
18
The Natural History of Parapharyngeal Solitary Fibrous Tumor/Hemangiopericytoma: A Case Report. 61
33530739 2021
19
Aggressive Behavior Predictors in Solitary Fibrous Tumor: Demographic, Clinical, and Histopathologic Characteristics of 81 Cases. 61
33512676 2021
20
Clinical applications of the endoscopic transorbital approach for various lesions. 61
33394139 2021
21
Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy? 61
32988268 2021
22
Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review. 61
33446319 2021
23
Central nervous system solitary fibrous tumour/hemangiopericytoma presenting as nausea, vomiting and hepatic dysfunction after the first trimester of pregnancy: A case report. 61
33511039 2021
24
Solitary fibrous tumor of the orbital region: report of a case with emphasis on the diagnostic utility of STAT-6. 61
33393522 2020
25
[Clinicopathological and molecular features of biphenotypic sinonasal sarcoma]. 61
33287510 2020
26
Fulminant hemangiopericytoma of the larynx - a case report and a review of the literature. 61
28549871 2020
27
[What's new in the management of meningeal solitary fibrous tumor/hemangiopericytoma?] 61
33160607 2020
28
Solitary Fibrous Tumor of the Orbit: A Clinicopathologic Study of Two Cases With Review of the Literature. 61
33144480 2020
29
Myopericytoma arising from myopericytosis-a hitherto unrecognized entity within the lung. 61
33244708 2020
30
Analysis of the inflammatory tumor microenvironment in meningeal neoplasms. 61
32831157 2020
31
Outcome of Epidural Hematoma: Lessons from Solitary Fibrous Tumor/Hemangiopericytoma. 61
32750517 2020
32
Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review. 61
33311794 2020
33
Atypical meningeal hemangiopericytoma presenting with punched-out calvarial erosion. 61
32944112 2020
34
Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE. 61
33188613 2020
35
Signal value difference between white matter and tumor parenchyma in T1- and T2- weighted images may help differentiating solitary fibrous tumor/ hemangiopericytoma and angiomatous meningioma. 61
32947194 2020
36
A Rare Case of a Primary Spinal Solitary Fibrous Tumor/Hemangiopericytoma in a 9-Month-Old Patient. 61
33159031 2020
37
A dedifferentiated intracranial solitary fibrous tumor with osteosarcoma components: rapid tumor progression and lethal clinical course. 61
32740753 2020
38
A Case of Intracranial Solitary Fibrous Tumor/Hemangiopericytoma Repeatedly Misdiagnosed as Hypertensive Intracerebral Hemorrhage. 61
32648385 2020
39
Hemangiopericytoma of meningo-fronto-naso-orbito-maxillary complex. 61
33012722 2020
40
A Footprint-Like Intracranial Solitary Fibrous Tumor/Hemangiopericytoma With Extracranial Extension and Acute Intratumoral Hemorrhage. 61
32472878 2020
41
Rare Primary Malignant Bone Sarcomas. 61
33114111 2020
42
Grade III Solitary Fibrous Tumor/Hemangiopericytoma: A Rare Case of a World Health Organization Grade III Anaplastic Hemangiopericytoma. 61
33194492 2020
43
An audit of brain tumor patients treated in 5 years at a single institute: Our regional cancer center experience. 61
33342814 2020
44
Solitary Fibrous Tumor of the Vulva: Case Report of a Rare Entity and Review of Literature. 61
32925444 2020
45
Clinical management of extrapleural septal solitary fibrous tumor: A case report. 61
32782564 2020
46
Sinonasal FUS-ERG-Rearranged Ewing's Sarcoma Mimicking Glomangiopericytoma. 61
33442361 2020
47
Hypervascular Pelvic Hemangiopericytoma Successfully Excised Without Embolization. 61
33364711 2020
48
Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma Penetrating the Skull Bone: An Unusual Presentation. 61
32474097 2020
49
The Importance of STAT6 in a Schwannoma-like Grade III Solitary Fibrous Tumor/Hemangiopericytoma Located in the Cerebellopontine Angle and Meckel's Cave. 61
32526357 2020
50
Rare meningeal-derived malignant hemangiopericytoma/solitary fibrous tumor grade II-III presenting as a subcutaneous mass on the scalp. 61
32885013 2020

Variations for Hemangiopericytoma, Malignant

Cosmic variations for Hemangiopericytoma, Malignant:

9 (show all 12)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM89629521 SF3B1 soft tissue,blood vessel,other,benign c.2014G>T p.A672S 2:197402619-197402619 6
2 COSM87508264 NCOR1 soft tissue,blood vessel,other,benign c.3838G>T p.G1280W 17:16072202-16072202 6
3 COSM101155459 NCOR1 soft tissue,blood vessel,other,benign c.3886G>T p.G1296W 17:16072202-16072202 6
4 COSM101210927 NCOR1 soft tissue,blood vessel,other,benign c.3559G>T p.G1187W 17:16072202-16072202 6
5 COSM144457442 MSH6 soft tissue,blood vessel,other,benign c.2309G>A p.G770D 2:47803462-47803462 6
6 COSM131472690 MSH6 soft tissue,blood vessel,other,benign c.2309G>A p.G770D 2:47803462-47803462 6
7 COSM85779643 MSH6 soft tissue,blood vessel,other,benign c.3215G>A p.G1072D 2:47803462-47803462 6
8 COSM144639336 MSH6 soft tissue,blood vessel,other,benign c.119G>A p.G40D 2:47803462-47803462 6
9 COSM132100831 MSH6 soft tissue,blood vessel,other,benign c.2825G>A p.G942D 2:47803462-47803462 6
10 COSM85400395 MAP2K2 soft tissue,blood vessel,other,benign c.979A>G p.N327D 19:4097284-4097284 6
11 COSM101413162 MAP2K2 soft tissue,blood vessel,other,benign c.688A>G p.N230D 19:4097284-4097284 6
12 COSM106234905 FBXO11 soft tissue,blood vessel,other,benign c.169+4733C>T p.? 2:47803462-47803462 6

Expression for Hemangiopericytoma, Malignant

Search GEO for disease gene expression data for Hemangiopericytoma, Malignant.

Pathways for Hemangiopericytoma, Malignant

GO Terms for Hemangiopericytoma, Malignant

Cellular components related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 SERPINA3 S100B PECAM1 MUC1 KIT IGF2
2 platelet alpha granule lumen GO:0031093 9.13 SERPINA3 IGF2 F13A1
3 cell-cell junction GO:0005911 8.92 PECAM1 NGFR KIT DES

Biological processes related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 S100B MDM2 KIT IGF2 FGF23
2 cytokine-mediated signaling pathway GO:0019221 9.65 VIM STAT6 MUC1 KIT F13A1
3 muscle filament sliding GO:0030049 9.5 VIM DES ACTC1
4 response to magnesium ion GO:0032026 9.37 MDM2 FGF23
5 platelet degranulation GO:0002576 9.26 SERPINA3 PECAM1 IGF2 F13A1
6 glomerular endothelium development GO:0072011 9.16 PECAM1 CD34
7 positive regulation of gene expression GO:0010628 9.1 VIM MDM2 KIT FGF23 CD34 ACTC1

Molecular functions related to Hemangiopericytoma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 VIM STAT6 SSX2 SSX1 SS18 SERPINA3

Sources for Hemangiopericytoma, Malignant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....